Viatris (MIL:1VTRS) Beta: N/A (As of Jun. 29, 2026)


MIL:1VTRS Viatris Inc MIL:1VTRS
30 GF Score
Price €14.33
GF Value €9.66
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Viatris Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-29), Viatris's Beta is Not available.

Viatris  (MIL:1VTRS) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Viatris Beta Related Terms

Viatris Beta Historical Data

* Premium members only.

The historical data trend for Viatris's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris Beta Chart

Viatris Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Viatris Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MIL:1VTRS
30GF Score
Viatris Inc MIL:1VTRS
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viatris Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Viatris (MIL:1VTRS) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of €14.33 is trading 48.3% above its estimated GF Value™ of €9.66. GuruFocus considers Viatris to be Significantly Overvalued.

Key valuation signals for MIL:1VTRS:

  • Beta: N/A
  • GF Value™: €9.66 vs. price of €14.33 (48.3% above fair value)
  • GF Score™: 30/100 with 8 warning signs

No single metric tells the full story. See the MIL:1VTRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
30GF Score

Get the complete analysis for MIL:1VTRS

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.33
Price
€9.66
GF Value